ICER study comes up with mixed findings on Dupixent and Eucrisa in atopic dermatitis

The USA’s Institute for Clinical and Economic Review (ICER), a non-profit organization, has released an Evidence Report assessing the comparative clinical effectiveness and value of dupilumab and crisaborole for the treatment of atopic dermatitis.

The report evaluates the evidence on Dupixent (dupilumab), from Sanofi (Euronext: SAN) and Regeneron (Nasdaq: REGN), an injectable treatment for moderate-to-severe atopic dermatitis, and Eucrisa (crisaborole) from Pfizer (NYSE: PFE), a topical treatment for mild-to-moderate atopic dermatitis, focusing on the clinical benefits, side effects, and value of these therapies compared to other treatment options available.

The US Food and Drug Administration approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis) in March this year, while Eucrisa was cleared for marketing by the FDA in December 2016.